FAQ

More QuickView FAQs

QuickView

0
Meta-
Analysis

Bookmark Forward

QuickView for Famotidine (compound)

Summary
General Info

PubChem

PubChem Compound 3325

Name:	Famotidine
PubChem Compound ID:	3325
Description:	A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Molecular formula:	C₈H₁₅N₇O₂S₃
Molecular weight:	337.449 g/mol
Synonyms:	Famodin; Novo-Famotidine; Famotidine (JP15/USP); Famodil; N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide; Cepal; Ferotine; Ulceprax; Pepzan; Invigan. show more » Famodin; Novo-Famotidine; Famotidine (JP15/USP); Famodil; N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide; Cepal; Ferotine; Ulceprax; Pepzan; Invigan; D00318; Famotin; Panalba; Fanox; SPBio_001251; Famodar; Ulfam; KBioGR_000676; Huberdina; Famodine; Farmotex; Brolin; KBio1_000545; Propanimidamide, N'-(aminosulfonyl)-3-(((2-((diaminomethylene)amino)-4-thiazoly)methyl)thio)-; Dinul; Propanimidamide, 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)-; Famotidinum [Latin]; Gastrion; Hacip; Spectrum4_000408; Mosul; Peptidin; Ulcatif; Blocacid; Gastrodomina; Vagostal; Spectrum3_001427; Ulgarine; Spectrum_001242; Famocid; Duovel; Famox; KBio3_002354; L 643341; Tipodex; HSDB 3572; Prestwick1_000104; Ulfinol; Famos; Rubacina; 76824-35-6; Yamarin; Gastrosidin; Pepdul; Purifam; Famoxal; Tamin; Logos; Famotal; N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]propanimidamide; Pepcidin Rapitab; Nevofam; Famotidine; Confobos; Sedanium-R; YM 11170; Mylanta AR; Mensoma; Nu-Famotidine; 3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide; Gaster; Ganor; Pepfamin; Peptan; Evatin; Peptifam; Dipsin; Cuantin; KBio2_001722; Notidin; KBio2_006858; Fanobel; KBioSS_001722; Famonit; Whitidin; NINDS_000545; Famtac; Motiax; 3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine; Famo; Gastrofam; SPBio_002027; Fibonel; KBio2_004290; Quamtel; Pepcid; Famotidina [Spanish]; Quamatel; Apo-Famotidine; Pepcid AC; Midefam; CHEBI:4975; Famowal; Ulcofam; Renapepsa; Famosan; MK 208; YM-11170; Apogastine; Fadine; Neocidine; Bestidine; Fagastine; Famotidine [USAN:BAN:INN:JAN]; Pepcidac; Fadyn; (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide; Lecedil; Famopsin; Pepcid (TN); Dispronil; Pepcidin; Restadin; Fanosin; Pepcidina; H2 Bloc; Durater; DivK1c_000545; Cronol; Ingastri; Pepcidine; Fadin; Dibrit 40; Topcid; Famogard; Pepdine; Antodine; Rogasti; Gastridin; Ulfagel; Famulcer; Weimok; Prestwick0_000104; Gastridan; Muclox; Ulfamid; Pepdif; Supertidine; Fudone; Propanimidamide, N'-(aminosulfonyl)-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)-; Gastropen; Sigafam; Digervin; Famotep; Gastro; Spectrum2_001036; Amfamox; Nulcerin; Nulceran; Famovane; Tairal; Dispromil show less «

DrugBank

Identification

Name:	Famotidine
Name (isomeric):	DB00927
Drug Type:	small molecule
Description:	A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Synonyms:	Famotidinum [Latin]; Famotidina [Spanish]
Brand:	Gastrosidin, Famodin, Famodil, Weimok, Tipodex, Famodar, Peptan, Apogastine, Nulceran, Famopsin, Fadin, Sedanium-R, Rubacina, Ulfinol, Nulcerin, Famovane, Amfamox, Whitidin, Pepcid RPD, Ulgarine, Cuantin, Famoxal, Pepdul, Motiax, Dispronil, Ulfam, Evatin, Huberdina, Durater, Dispromil, Lecedil, Purifam, Invigan, Fanox, Cepal, Mensoma, Brolin, Novo-Famotidine, Mosul, Nu-Famotidine, Panalba, Fanosin, Famtac, Ulfagel, Gaster, Antodine, Pepcidin, Pepcidine, Gastrofam, Famosan, Pepcidina, Famotep, Pepfamin, Fadyn, Quamatel, Muclox, Famonit, Pepcid AC, Tairal, Famocid, Topcid, Duovel, Ferotine, Fudone, Fadine, Yamarin, Famos, Famox, Peptidin, Gastrodomina, Hacip, Dinul, Logos, Ulceprax, Fanobel, Famodine, Dipsin, Famulcer, Famo, Ulcofam, Fluxid, Famotin, Sigafam, Famowal, Bestidine, Vagostal, Pepdif, Peptifam, Nevofam, Gastro, Pepcid, Ulfamid, Farmotex, Renapepsa, Famotal, Dibrit 40, Tamin, Ingastri, Cronol, Ganor, Confobos, Neocidine, Pepzan, Blocacid, Gastridin, Gastropen, Midefam, Fagastine, Mylanta AR, Gastridan, H2 Bloc, Pepdine, Quamtel, Apo-Famotidine, Gastrion, Rogasti, Pepcidin Rapitab, Ulcatif, Digervin, Supertidine, Notidin, Famogard, Restadin, Fibonel
Category:	Anti-Ulcer Agents, Histamine H2 Antagonists
CAS number:	76824-35-6

Pharmacology

Indication:	For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).
Pharmacology:	Famotidine, a competitive histamine H₂-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an incr... show more » Famotidine, a competitive histamine H₂-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. show less «
Mechanism of Action:	Famotidine binds competitively to H₂-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including foo... show more » Famotidine binds competitively to H₂-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. show less «
Absorption:	The bioavailability of oral doses is 40-45%.
Protein binding:	15-20%
Biotransformation:	Hepatic.
Route of elimination:	Renal clearance is 250-450 mL/min, indicating some tubular excretion.
Half Life:	2.5-3.5 hours
Clearance:	renal cl=250-450 mL/min
Toxicity:	Intravenous, mouse: LD₅₀ = 244.4mg/kg; Oral, mouse: LD₅₀ = 4686 mg/kg. Symptoms of overdose include emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse.
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Avoid alcohol.

Take without regard to meals, food may slightly increase the product's bioavailability.

Limit caffeine intake.

Drug interaction:

Atazanavir	This gastric pH modifier decreases the levels/effects of atazanavir
Itraconazole	The H2-receptor antagonist, famotidine, may decrease the absorption of itraconazole.
Enoxacin	Famotidine may decrease the absorption of enoxacin.
Cefditoren	H2-Antagonists such as famotidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
Ketoconazole	The H2-receptor antagonist, famotidine, may decrease the absorption of ketoconazole.

Targets

Histamine H2 receptor

The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) signaling pathway

UniProt ID:

P25021

Gene:

HRH2

Actions:

antagonist

References:

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
View Article

Fukuda M, Tanaka S, Suzuki S, Kusama K, Kaneko T, Sakashita H: Cimetidine induces apoptosis of human salivary gland tumor cells. Oncol Rep. 2007 Mar;17(3):673-8.
View Article

Takahashi HK, Watanabe T, Yokoyama A, Iwagaki H, Yoshino T, Tanaka N, Nishibori M: Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol. 2006 Aug;70(2):450-3. Epub 2006 May 24.
View Article

Kesiova M, Alexandrova A, Yordanova N, Kirkova M, Todorov S: Effects of diphenhydramine and famotidine on lipid peroxidation and activities of antioxidant enzymes in different rat tissues. Pharmacol Rep. 2006 Mar-Apr;58(2):221-8.
View Article

Lesclous P, Schramm F, Gallina S, Baroukh B, Guez D, Saffar JL: Histamine mediates osteoclastic resorption only during the acute phase of bone loss in ovariectomized rats. Exp Physiol. 2006 May;91(3):561-70. Epub 2006 Mar 2.
View Article

Amagase K, Okabe S: On the mechanisms underlying histamine induction of gastric mucosal lesions in rats with partial gastric vascular occlusion. J Pharmacol Sci. 2003 Jun;92(2):124-36.
View Article

Weydert JA, Ball TM, Davis MF: Systematic review of treatments for recurrent abdominal pain. Pediatrics. 2003 Jan;111(1):e1-11.
View Article

Miyata K, Kamato T, Nishida A, Honda K: Studies on the mechanism for the gastric mucosal protection by famotidine in rats. Jpn J Pharmacol. 1991 Feb;55(2):211-22.
View Article

Leurs R, Brozius MM, Smit MJ, Bast A, Timmerman H: Effects of histamine H1-, H2- and H3-receptor selective drugs on the mechanical activity of guinea-pig small and large intestine. Br J Pharmacol. 1991 Jan;102(1):179-85.
View Article

Inan A, Sen M, Surgit O, Ergin M, Bozer M: Effects of the histamine H2 receptor antagonist famotidine on the healing of colonic anastomosis in rats. Clinics (Sao Paulo). 2009;64(6):567-70.
View Article

Ojiako K, Shingala H, Schorr C, Gerber DR: Famotidine versus pantoprazole for preventing bleeding in the upper gastrointestinal tract of critically ill patients receiving mechanical ventilation. Am J Crit Care. 2008 Mar;17(2):142-7.
View Article

Enzymes

Cytochrome P450 2C19

Transporters

Solute carrier family 22 member 2

Solute carrier family 22 member 8